Design Therapeutics, Inc. DSGN Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Design Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Design Therapeutics, Inc.'s investing cash flow?
- Design Therapeutics, Inc. (DSGN) reported investing cash flow of -$7.59M in Q1 2026.
- How has Design Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Design Therapeutics, Inc.'s investing cash flow decreased by 196.4% year-over-year, from $7.87M to -$7.59M.
- What is the long-term trend for Design Therapeutics, Inc.'s investing cash flow?
- Over 2 years (2021 to 2023), Design Therapeutics, Inc.'s investing cash flow has grown at a -1.0% compound annual growth rate (CAGR), from -$53.64M to $52.54M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.